Company: BDRX
Filing Date: 2025-11-17
Form Type: POS AM
Source: 0001214659-25-016809
Chunk: 96

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-11-17
Form: POS AM
Chunk 96
---
 on the principal trading market or any other stock exchange, market or trading facility on which the
securities are traded or in private transactions. These sales may be at fixed or negotiated prices. A selling shareholder may use any
one or more of the following methods when selling securities:

| · | ordinary brokerage transactions and transactions in which the broker-dealer solicits purchasers; |

| · | block trades in which the broker-dealer will attempt to sell the securities as agent but may position 
 and resell a portion of the block as principal to facilitate the transaction;                         |

| · | purchases by a broker-dealer as principal and resale by the broker-dealer for its account; |

| · | an exchange distribution in accordance with the rules of the applicable exchange; |

| · | privately negotiated transactions; |

| · | settlement of short sales; |

| · | in transactions through broker-dealers that agree with the selling shareholders to sell a specified number 
 of such securities at a stipulated price per security;                                                     |

| · | through the writing or settlement of options or other hedging transactions, whether through an options 
 exchange or otherwise;                                                                                 |

| · | a combination of any such methods of sale; or |

| · | any other method permitted pursuant to applicable law. |

The selling shareholders may also sell
securities under Rule 144 or any other exemption from registration under the Securities Act, if available, rather than under this prospectus.

Broker-dealers engaged by the selling shareholders
may arrange for other brokers-dealers to participate in sales. Broker-dealers may receive commissions or discounts from the selling shareholders
(or, if any broker-dealer acts as agent for the purchaser of securities, from the purchaser) in amounts to be negotiated, but, except
as set forth in a supplement to this Prospectus, in the case of an agency transaction not in excess of a customary brokerage commission
in compliance with FINRA Rule 2440; and in the case of a principal transaction a markup or markdown in compliance with FINRA IM-2440.

In connection with the sale of the securities
or interests therein, the selling shareholders may enter into hedging transactions with broker-dealers or other financial institutions,
which may in turn engage in short sales of the securities in the course of hedging the positions they assume. The selling shareholders
may also sell securities short and deliver these securities to close out their short positions, or loan or pledge the securities to broker-dealers
that in turn may sell these securities. The selling shareholders